Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors
Status:
Recruiting
Trial end date:
2022-12-21
Target enrollment:
Participant gender:
Summary
Positron emission tomography (PET) molecular imaging provides a valuable tool for the
diagnosis and differential diagnosis, staging of various tumors. Malignant tumor is composed
of tumor cells and tumor stroma, which occupies the vast majority of the tumor.
Cancer-associated fibroblasts (CAF) are an important part of the tumor stroma. Fibroblast
activation protein (FAP) is over-expressed in CAF, which is closely related to tumor growth,
invasion, metastasis, immunosuppression and prognosis; and the expression level of FAP in
normal tissues and organs is very low. So it becomes an excellent target for cancer diagnosis
and treatment. Radionuclide-labeled fibroblast activation protein inhibitors (FAPI) that
specifically target to FAP as a tracer for PET imaging can be applied for targeted diagnosis
and treatment of cancer. Recently, some studies have found that gallium-68 (68Ga) -FAPI as a
new novel positron tracer has shown to be with good application potential. In this
prospective study, the investigators will use integrated PET/MR, and PET/CT with the agent
68Ga-FAPI and conventional imaging agent [F-18] fluorodeoxyglucose (18F-FDG) to diagnose and
stage various cancers, the aim is to make up for the deficiency in FDG PET imaging in the
diagnosis and staging of some cancers.